Therapeutic drug monitoring - Antiepileptic drugs

British Journal of Clinical Pharmacology

Volumn 52, Issue SUPPL. 1, 2001, Pages

  Eadie, M J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antiepileptic drugs; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LEVETRIACETAM; METHYLPHENOBARBITAL; OXACARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SULTIAME; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ARTICLE; BLOOD SAMPLING; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; EPILEPSY; HUMAN; MAXIMUM ALLOWABLE CONCENTRATION; METHODOLOGY; PRIORITY JOURNAL; SEIZURE; STEADY STATE; TOXICITY;

EID: 0034851392     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.00394.x     Document Type: Article

References (75)

1. Anticonvulsant serum levels are useful only if the physician appropriately uses them: An assessment of the impact of providing serum level data to physicians
2. Overuse of monitoring of blood concentrations of antiepileptic drugs
3. Level off
4. Antiepileptic drug monitoring: A reappraisal
5. Appropriateness of antiepileptic drug level monitoring
6. How worthwhile is plasma primidone measurement?
7. Assay and pharmacokinetics of clonazepam in humans
8. Phenobarbital: Studies f elimination, accumulation, tolerance and dosage schedules
9. Studies on 5-5′-diphenylhydantoin (Dilantin) in animals and man
10. Determination of diphenylhydantoin and phenobarbital in small amounts of serum
11. Spectrophotometric determination of diphenylhydantoin
12. Influence of ethylphenacemide on serum levels of other anti-epileptic drugs
13. Quantitative enzyme immunoassay: Current status
14. Automated homogeneous liposome immunoassay systems for anticonvulsant drugs
15. Fluorescence polarization immunoassay. IV. Determination of phenytoin and phenobarbital in human serum and plasma
16. A rate nephelometric phenobarbital and phenytoin assay: Analytical and correlation studies of a new single-point calibration immunoprecipitation inhibition method
17. Substrate-labelled fluorescent immunoassay for phenytoin in human serum
18. Application of electron spin resonance to determination of serum drug concentrations
19. Determination of total and free plasma carbamazepine concentrations by enzyme multiplied immunoassay
20. Interference in immunoassay measurements of total and free phenytoin in uremic patients: A reappraisal
21. Capillary electrophoresis for therapeutic drug monitoring of antiepileptics
22. Measurement of anticonvulsants and their metabolites in biological fluids
23. Erythrocyte uptake and plasma protein binding of diphenylhydantoin
24. Plasma protein binding of carbamazepine
25. Pitfalls in the determination of unbound carbamazepine concentrations in plasma
26. Comparison of the Amicon Centrifree micropartition system with the Sartofius SM 13249E Centrisart I device to determine protein free phenytoin concentrations
27. Effect of separator tubes on free and total phenytoin and carbamazepine serum concentrations
28. Tears as the best practical indicator of the unbound fraction of an anticonvulsant drug
29. Diphenylhydantoin and primidone in tears
30. Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin
31. The place of saliva in antiepileptic drug monitoring
32. Factors influencing plasma phenobarbitone levels in epileptic patients
33. Salivary levels of anticonvulsants: A practical approach to drug monitoring
34. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers
35. Flow-dependent salivary primidone levels in epileptic children
36. Effect of saliva flow rate on phenytoin concentrations: Implications for therapeutic monitoring
37. Fallacious results from measuring salivary carbamazepine concentrations
38. Fluctuation of plasma phenytoin levels on single dose and twice daily dosage regimes
39. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects
40. Early stage autoinduction of carbamazepine metabolism in humans
41. Dose-dependent metabolism of carbamazepine in humans
42. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin
43. Apparent autoinduction of valproate β-oxidation in humans
44. Therapeutic drug monitoring of phenytoin. Rationale and current status
45. Therapeutic, toxic and fatal blood concentration ranges of antiepileptic drugs as an aid to the interpretation of analytical data
46. Plasma antiepileptic drug monitoring in a neurological practice: A 25-year experience
47. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine
48. Carbamazepine therapy in trigeminal neuralgia. Clinical effects in relation to plasma concentration
49. Relationship between plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effect
50. If a stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective survey
51. Plasma concentrations of unbound valproate and the management of epilepsy
52. Ethosuximide enantiomers in pregnancy and lactation
53. Plasma vigabatrin enantiomer ratios in adults and children
54. Gas chromatographic assay of vigabatrin enantiomers in plasma
55. High performance liquid chromatographic analysis of vigabatrin enantiomers in human serum by precolumn derivatization with o-phataldialdehyde-N-acetyl-L-cysteine and fluorescence detection
56. Antiepileptic drugs. A review of clinically significant drug interactions
57. Plasma level monitoring of anticonvulsants
58. Explanation of the dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation
59. The pharmacokinetics of carbamazepine
60. Pharmacokinetics of drugs used for petit mal absence epilepsy
61. Valproic acid dosage and plasma protein binding and clearance
62. Indications for plasma drug monitoring in patients with epilepsy. Implications for reducing costs
63. A multicentre randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy
64. Therapeutic monitoring of the new antiepileptic drugs
65. General principles. How to use antiepileptic drugs
66. Lamotrigine and therapeutic drug monitoring: Retrospective survey following the introduction of a routine service
67. Daily salivary anticonvulsant monitoring in patients with intractable epilepsy
68. Possible roles for frequent salivary antiepileptic drug monitoring in the management of epilepsy
69. Further observations on carbamazepine plasma levels in epileptic patients
70. Ethosuximide in the treatment of absence (petit mal) seizures
71. The relation of anticonvulsant drug levels to complete seizure control
72. Management of epilepsy with diphenylhydantoin sodium
73. Pharmacokinetics of di-n-propylacetate in epileptic patients
74. Vigabatrin. Chemistry, absorption, distribution, and elimination